Some adverse reactions to cosmetic procedures occur more often in patients with darker skin types. Patients should be counseled on appropriate cosmetic procedures for their skin type, according to Cheryl M. Burgess, M.D., at the Skin of Color Update virtual meeting.
Superficial radiation offers a newer, FDA-approved office-based option that is safe. Steven A. Davis, M.D., shares his experience using surface radiotherapy to treat his patients with non-melanoma skin cancer.
A recent study showed that curettage and cryotherapy, and electrodesiccation and curettage are two techniques that have comparable cure rates. The study’s findings highlight the efficacy and reliability of these treatment approaches for minimally invasive cutaneous carcinomas.
The 21-member global ROSacea Consensus panel developed updated recommendations for rosacea, diagnosis, classification and management to support and promote transition to a phenotype approach in rosacea.
The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.
Since the start of the pandemic, dermatologists have seen an average 50% drop in patient volume. While teledermatology has offered a channel for non-urgent patients and patient visits are rebounding, overall patient volumes are still significantly lower than 2019.
A retrospective review of patients seen in an academic dermatology clinic over a one-year period identified 20 individuals with nasal papules in association with acne, which are thought to represent scarring sequelae. The condition is underrecognized, researchers say and requires further research to better understand.
Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.